RT Journal Article
SR Electronic
T1 Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e241634
DO 10.1136/bcr-2021-241634
VO 14
IS 5
A1 Darren Wong
A1 William Thomas
A1 Andrew Butler
A1 Lisa Sharkey
YR 2021
UL http://casereports.bmj.com/content/14/5/e241634.abstract
AB A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. The patient was successfully treated with bortezomib, a proteasome inhibitor, and has remained well as an outpatient without evidence of ongoing haemolysis.